Mario Sznol, MD
Immune checkpoint inhibitors (ICIs) combined with the anti–CTLA-4 agent ipilimumab (Yervoy) have dramatically improved survival in metastatic melanoma, but resistance and lack of response remain obstacles to wider efficacy, Mario Sznol, MD, said in a presentation during the 4th Annual
International Congress on Immunotherapies in Cancer®
. Multiple efforts are under way to understand these issues better and develop improved biomarkers for response, Sznol added.
... to read the full story